179 related articles for article (PubMed ID: 34885110)
1. Overexpression of Cystine/Glutamate Antiporter xCT Correlates with Nutrient Flexibility and ZEB1 Expression in Highly Clonogenic Glioblastoma Stem-like Cells (GSCs).
Koch K; Hartmann R; Suwala AK; Rios DH; Kamp MA; Sabel M; Steiger HJ; Willbold D; Sharma A; Kahlert UD; Maciaczyk J
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885110
[TBL] [Abstract][Full Text] [Related]
2. High cell density increases glioblastoma cell viability under glucose deprivation via degradation of the cystine/glutamate transporter xCT (SLC7A11).
Yamaguchi I; Yoshimura SH; Katoh H
J Biol Chem; 2020 May; 295(20):6936-6945. PubMed ID: 32265299
[TBL] [Abstract][Full Text] [Related]
3. The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate.
Koppula P; Zhang Y; Shi J; Li W; Gan B
J Biol Chem; 2017 Aug; 292(34):14240-14249. PubMed ID: 28630042
[TBL] [Abstract][Full Text] [Related]
4. Cystine uptake through the cystine/glutamate antiporter xCT triggers glioblastoma cell death under glucose deprivation.
Goji T; Takahara K; Negishi M; Katoh H
J Biol Chem; 2017 Dec; 292(48):19721-19732. PubMed ID: 29038291
[TBL] [Abstract][Full Text] [Related]
5. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
[TBL] [Abstract][Full Text] [Related]
6. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility.
Shin CS; Mishra P; Watrous JD; Carelli V; D'Aurelio M; Jain M; Chan DC
Nat Commun; 2017 Apr; 8():15074. PubMed ID: 28429737
[TBL] [Abstract][Full Text] [Related]
7. Negative regulation of osteoblastogenesis through downregulation of runt-related transcription factor-2 in osteoblastic MC3T3-E1 cells with stable overexpression of the cystine/glutamate antiporter xCT subunit.
Uno K; Takarada T; Takarada-Iemata M; Nakamura Y; Fujita H; Hinoi E; Yoneda Y
J Cell Physiol; 2011 Nov; 226(11):2953-64. PubMed ID: 21302293
[TBL] [Abstract][Full Text] [Related]
8. The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer.
Jyotsana N; Ta KT; DelGiorno KE
Front Oncol; 2022; 12():858462. PubMed ID: 35280777
[TBL] [Abstract][Full Text] [Related]
9. Redox-dependent AMPK inactivation disrupts metabolic adaptation to glucose starvation in xCT-overexpressing cancer cells.
Lee Y; Itahana Y; Ong CC; Itahana K
J Cell Sci; 2022 Aug; 135(15):. PubMed ID: 35775474
[TBL] [Abstract][Full Text] [Related]
10. A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options.
Criscuolo D; Morra F; Celetti A
Explor Target Antitumor Ther; 2022; 3(5):570-581. PubMed ID: 36338517
[TBL] [Abstract][Full Text] [Related]
11. ROS Mediate xCT-Dependent Cell Death in Human Breast Cancer Cells under Glucose Deprivation.
Chen MC; Hsu LL; Wang SF; Hsu CY; Lee HC; Tseng LM
Cells; 2020 Jul; 9(7):. PubMed ID: 32630312
[TBL] [Abstract][Full Text] [Related]
12. Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation.
Lehnhardt FG; Bock C; Röhn G; Ernestus RI; Hoehn M
NMR Biomed; 2005 Oct; 18(6):371-82. PubMed ID: 15959923
[TBL] [Abstract][Full Text] [Related]
13. Suppression by glutamate of proliferative activity through glutathione depletion mediated by the cystine/glutamate antiporter in mesenchymal C3H10T1/2 stem cells.
Iemata M; Takarada T; Hinoi E; Taniura H; Yoneda Y
J Cell Physiol; 2007 Dec; 213(3):721-9. PubMed ID: 17520696
[TBL] [Abstract][Full Text] [Related]
14. Salubrinal Enhances Cancer Cell Death during Glucose Deprivation through the Upregulation of xCT and Mitochondrial Oxidative Stress.
Chen MC; Hsu LL; Wang SF; Pan YL; Lo JF; Yeh TS; Tseng LM; Lee HC
Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572286
[TBL] [Abstract][Full Text] [Related]
15. Perturbation of the glutamate-glutamine system in alcohol dependence and remission.
Thoma R; Mullins P; Ruhl D; Monnig M; Yeo RA; Caprihan A; Bogenschutz M; Lysne P; Tonigan S; Kalyanam R; Gasparovic C
Neuropsychopharmacology; 2011 Jun; 36(7):1359-65. PubMed ID: 21389979
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor promotes glioblastoma cell death under glucose deprivation via upregulation of xCT (SLC7A11).
Yamamoto M; Teramoto K; Katoh H
Cell Signal; 2021 Feb; 78():109874. PubMed ID: 33285240
[TBL] [Abstract][Full Text] [Related]
17. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance.
Lim JKM; Delaidelli A; Minaker SW; Zhang HF; Colovic M; Yang H; Negri GL; von Karstedt S; Lockwood WW; Schaffer P; Leprivier G; Sorensen PH
Proc Natl Acad Sci U S A; 2019 May; 116(19):9433-9442. PubMed ID: 31000598
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models.
Barutello G; Di Lorenzo A; Gasparetto A; Galiazzi C; Bolli E; Conti L; Cavallo F
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359363
[TBL] [Abstract][Full Text] [Related]
19. Engagement of cellular prion protein with the co-chaperone Hsp70/90 organizing protein regulates the proliferation of glioblastoma stem-like cells.
Iglesia RP; Prado MB; Cruz L; Martins VR; Santos TG; Lopes MH
Stem Cell Res Ther; 2017 Apr; 8(1):76. PubMed ID: 28412969
[TBL] [Abstract][Full Text] [Related]
20. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
